DE60038099T2 - Neisseria impfstoffzusammensetzungen und methoden - Google Patents

Neisseria impfstoffzusammensetzungen und methoden Download PDF

Info

Publication number
DE60038099T2
DE60038099T2 DE60038099T DE60038099T DE60038099T2 DE 60038099 T2 DE60038099 T2 DE 60038099T2 DE 60038099 T DE60038099 T DE 60038099T DE 60038099 T DE60038099 T DE 60038099T DE 60038099 T2 DE60038099 T2 DE 60038099T2
Authority
DE
Germany
Prior art keywords
neisseria
vaccine composition
lactamica
commensal
outer membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60038099T
Other languages
German (de)
English (en)
Other versions
DE60038099D1 (de
Inventor
Andrew Salisbury ROBINSON
Andrew Richard Salisbury GORRINGE
Michael John Salisbury HUDSON
Philippa Salisbury BRACEGIRDLE
John Simon Kroll
Keith Cartwright
Steven Anthony Rochford Subiaco WEBB
Paul Richard Langford
Cliona Anne O'dwyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Public Health England
Original Assignee
Health Protection Agency
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904028.9A external-priority patent/GB9904028D0/en
Priority claimed from GBGB9922561.7A external-priority patent/GB9922561D0/en
Application filed by Health Protection Agency, Imperial Innovations Ltd filed Critical Health Protection Agency
Application granted granted Critical
Publication of DE60038099D1 publication Critical patent/DE60038099D1/de
Publication of DE60038099T2 publication Critical patent/DE60038099T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE60038099T 1999-02-22 2000-02-22 Neisseria impfstoffzusammensetzungen und methoden Expired - Lifetime DE60038099T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9904028.9A GB9904028D0 (en) 1999-02-22 1999-02-22 Neisserial vaccine
GB9904028 1999-02-22
GBGB9922561.7A GB9922561D0 (en) 1999-09-23 1999-09-23 Neisserial vaccine compositions and methods
GB9922561 1999-09-23
PCT/GB2000/000624 WO2000050074A2 (en) 1999-02-22 2000-02-22 Neisserial vaccine compositions and methods

Publications (2)

Publication Number Publication Date
DE60038099D1 DE60038099D1 (de) 2008-04-03
DE60038099T2 true DE60038099T2 (de) 2009-02-19

Family

ID=26315168

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60038099T Expired - Lifetime DE60038099T2 (de) 1999-02-22 2000-02-22 Neisseria impfstoffzusammensetzungen und methoden

Country Status (12)

Country Link
US (1) US7157245B2 (enExample)
EP (2) EP1852125A3 (enExample)
JP (1) JP4982009B2 (enExample)
AT (1) ATE386541T1 (enExample)
AU (1) AU779086B2 (enExample)
CA (1) CA2371928C (enExample)
CY (1) CY1107950T1 (enExample)
DE (1) DE60038099T2 (enExample)
DK (1) DK1154791T3 (enExample)
ES (1) ES2298128T3 (enExample)
PT (1) PT1154791E (enExample)
WO (1) WO2000050074A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1154791T3 (da) * 1999-02-22 2008-06-16 Health Prot Agency Neisseria-vaccinesammensætninger og fremgangsmåder
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
GB0007433D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Recombinant transferrin binding proteins
GB0107219D0 (en) * 2001-03-22 2001-05-16 Microbiological Res Authority Immunogenic commensal neisseria sequences
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
EP1374892A1 (en) * 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2005030122A2 (en) * 2003-08-13 2005-04-07 Chiron Corporation Inactivated host cell delivery of polynucleotides encoding immunogens
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9387239B2 (en) 2008-05-30 2016-07-12 U.S. Army Medical Research And Materiel Command Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
GB0922224D0 (en) 2009-12-21 2010-02-03 Hiltech Developments Ltd Transformation of commensal neisseria
US10900043B2 (en) 2014-09-02 2021-01-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating bacterial disease
US10286016B2 (en) 2014-09-02 2019-05-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating gonorrhea
GB201522153D0 (en) * 2015-12-15 2016-01-27 Univ Southampton Meningococcal infection and modified neisseria lactamica
US12005110B2 (en) 2019-02-14 2024-06-11 University Of Florida Research Foundation, Incorporated Honeybee commensal Snodgrassella alvi vaccine against pathogenic Neisseriaceae

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288617A (en) 1984-10-31 1994-02-22 Commonwealth Scientific And Industrial Research Organization Method of producing an antigenic preparation
US6737521B1 (en) * 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5470740A (en) * 1993-11-04 1995-11-28 Life Technologies, Inc. Cloned NsiI restriction-modification system
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
GB9811260D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel compounds
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US20030215469A1 (en) * 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
JP2003506007A (ja) * 1998-12-02 2003-02-18 ユニヴァーシティ オブ メリーランド，ボルチモア 抗原送達用プラスミド維持系
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
DK1154791T3 (da) * 1999-02-22 2008-06-16 Health Prot Agency Neisseria-vaccinesammensætninger og fremgangsmåder
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation

Also Published As

Publication number Publication date
JP4982009B2 (ja) 2012-07-25
AU779086B2 (en) 2005-01-06
EP1154791B1 (en) 2008-02-20
CY1107950T1 (el) 2013-09-04
CA2371928A1 (en) 2000-08-31
CA2371928C (en) 2013-08-13
EP1154791A2 (en) 2001-11-21
AU2681100A (en) 2000-09-14
EP1852125A2 (en) 2007-11-07
WO2000050074A2 (en) 2000-08-31
ATE386541T1 (de) 2008-03-15
EP1852125A3 (en) 2010-09-22
PT1154791E (pt) 2008-05-30
DK1154791T3 (da) 2008-06-16
DE60038099D1 (de) 2008-04-03
ES2298128T3 (es) 2008-05-16
JP2002537352A (ja) 2002-11-05
US20030026809A1 (en) 2003-02-06
WO2000050074A3 (en) 2000-12-28
US7157245B2 (en) 2007-01-02

Similar Documents

Publication Publication Date Title
DE60038099T2 (de) Neisseria impfstoffzusammensetzungen und methoden
DE69635783T2 (de) Antigen omp26 aus haemophilus influenzae
DE69534992T2 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DE60031974T2 (de) Abgeschwächte Mikroorganismen zur Behandlung von Infektionen
DE69333028T2 (de) Deletionsmutanten als impfstoffe gegen cholera
DE69932425T2 (de) Attenuierte salmonella mutanten, welche das vi-antigen konstant exprimieren
DE4192335C2 (de) T-Zell-Epitope
DE69735191T2 (de) Verfahren zur Herstellung multivalenter Impfstoffe
DE69327553T2 (de) E.Coli P-Fimbriae als immunogener Träger gegen GnRH
DE69419966T2 (de) Impstoff gegen Streptococcus suis-Infektion
DE60011560T2 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
DE69034107T2 (de) Impfstoffe gegen Bakterien, die zur Blutvergiftung führen
DE3855442T2 (de) Verfahren zur Gewinnung von Schutzantigenen gegen Bordetella-Infektionen und toxische Prozesse
DE69535422T2 (de) Vakzin für einen nicht typisierbaren Haemophilus influenzae Stamm
DE69330778T2 (de) Vogel-mycoplasmaantigen, sein gen, das gen enthaltender rekombinanter vektor, und damit hergestellter impfstoff
DE69631543T2 (de) Immunität gegen pasteurella haemolytica leukotoxin
US7081244B2 (en) Neisserial vaccine compositions and methods
DE69531186T2 (de) Antibordetella azellulärer Impfstoff
DE69524626T2 (de) Äusseres hauptmembranprotein cd von moraxella
DE69018702T2 (de) Verfahren zur Herstellung eines Antikaries-Impfstoffes aus Streptococcus mutans und Impfzusammensetzung gegen Karies in Form von Nasentropfen.
Lepper et al. Infectivity and virulence of Australian strains of Moraxella bovis for the murine and bovine eye in relation to pilus serogroup sub‐unit size and degree of piliation
DE60033291T2 (de) Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden
DE69933237T2 (de) Multikomponentimpfstoff mit mindestens zwei antigenen von haemophilus influenzae
DE69838838T2 (de) Lactoferrinrezeptoren von Moraxella
DE60037413T2 (de) Rekombinante adhesin-proteine aus haemophilus influenzae

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: ROBINSON, ANDREW, SALISBURY, WILTSHIRE SP4 0JG, GB

Inventor name: GORRINGE, ANDREW RICHARD, SALISBURY, WILTSHIRE, GB

Inventor name: HUDSON, MICHAEL JOHN, SALISBURY, WILTSHIRE SP4, GB

Inventor name: BRACEGIRDLE, PHILIPPA, SALISBURY, WILTSHIRE SP, GB

Inventor name: KROLL, JOHN SIMON, LONDON W2 1PG, GB

Inventor name: CARTWRIGHT, KEITH, LONDON NW9 5DF, GB

Inventor name: WEBB, STEVEN,ANTHONY,ROCHFORD, SUBIACO, WESTER, AU

Inventor name: LANGFORD, PAUL RICHARD, OXFORD OX1 4PT, GB

Inventor name: O'DWYER CLIONA ANNE, COUNTRY GALWAY, IE

8364 No opposition during term of opposition